Chiasma Files Mycapssa European Application For Acromegaly

Chiasma Inc CHMA submitted a marketing application to the European Medicines Agency seeking approval of Mycapssa (oral octreotide capsules) as maintenance therapy for adults with acromegaly.
The application is supported by positive results from Phase 3 MPOWERED non-inferiority trial comparing Mycapssa to long-acting injectable somatostatin analogs (iSSAs).
Recently, the company announced positive patient-reported outcomes data from its MPOWERED trial, demonstrating that study patients reported significantly improved quality of life and work productivity after transitioning from long-acting injectable somatostatin analogs to Mycapssa.
Price Action: CHMA shares are down 0.2% at $4.7 during the premarket session on the last check Tuesday.

Posted In:

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.